Inogen SEC filings document a respiratory medical technology business that develops, manufactures, markets, sells, and rents respiratory products for homecare use. Results filings and annual proxy materials cover operating performance, executive compensation, director elections, board committees, equity plans, and stockholder voting matters.
Recent Form 8-K disclosures also record share repurchase authorization, leadership and compensatory arrangements, material governance agreements, and Regulation FD communications. The filing record ties these corporate actions to Inogen’s common stock, board oversight, and product portfolio in portable oxygen, airway clearance, stationary oxygen, and CPAP categories.
Inogen (INGN) agreed to sell Rotech Healthcare substantially all assets used solely in its U.S. oxygen rental business, including specified inventory and related patient records, for estimated consideration of up to approximately $24.8 million. The amount is subject to post-closing reconciliation and payable in six installments. Closing is subject to customary conditions and expected in the fourth quarter of 2026.
Inogen also signed a long-term product supply agreement with Rotech. The share repurchase amendment is effective only upon closing; it would increase the total authorization from $30.0 million to $45.0 million, including prior repurchases, and extend the program through June 30, 2028. Rental Business revenue was $24.3 million in the first half of 2026, down 9.8% year over year. Inogen expects to present the business as discontinued operations beginning with third-quarter 2026 results, subject to its final accounting analysis.
Inogen Inc (INGN) reported that Mary E. Wright, its Vice President and Chief Accounting Officer, acquired 1,500 shares of Inogen common stock on September 1, 2026. The shares were acquired through the company’s 2014 Employee Stock Purchase Plan, bringing her directly held stake to 20,629 shares.
Inogen Inc (INGN) reported that executive vice president Kevin P. Smith completed multiple equity transactions on September 1, 2026, in connection with restricted stock units and the employee stock purchase plan, reported as made under a Rule 10b5-1 trading plan. An award of 18,136 restricted stock units was exercised into an equal number of common shares, with 8,671 of those shares withheld to satisfy tax withholding liability and 1,500 additional shares acquired through the 2014 Employee Stock Purchase Plan at $5.33 per share. Following the vesting event, 18,135 restricted stock units remain outstanding and subject to future vesting.
Inogen Inc (INGN) reports that CEO, President, and director Kevin Raymond Merrill Smith acquired 1,500 shares of common stock on September 1, 2026 through the company’s 2014 Employee Stock Purchase Plan at $5.33 per share. The filing shows he now directly owns 134,962 shares, with the transaction made under a Rule 10b5-1 trading plan.
Inogen, Inc. develops and rents respiratory products such as portable and stationary oxygen concentrators, airway clearance devices, and CPAP masks. For the three months ended June 30, 2026, revenue was 95,084 (amounts in thousands), up 3.0% from 92,277, driven by 5.5% growth in sales revenue and 14.8% growth in international sales, partly offset by an 11.8% decline in U.S. rental revenue due to fewer patients on service.
Total gross margin improved to 45.5% from 44.8%, as higher sales volumes and lower component and warranty costs lifted sales margins, while rental margins declined on higher logistics costs per patient. Operating expenses were 48,368, yielding a loss from operations of 5,096, compared with 6,129 a year earlier. Net loss for the quarter was 3,850 (basic and diluted EPS $(0.14)), and for the first six months net loss was 12,174 (EPS $(0.45)).
As of June 30, 2026, Inogen held 87,276 in cash and cash equivalents, 18,263 in marketable securities, and 1,303 in restricted cash, with total assets of 285,572 and stockholders’ equity of 174,864. Net cash used in operating activities improved to 3,739 for the first six months, from 12,440 in the prior-year period. Under a $30,000 share repurchase program authorized in February 2026, the company bought back and retired 1,145,150 shares for 7,498, leaving 22,502 available under the authorization.
Inogen, Inc. reported second quarter 2026 results with revenue of $95.1 million, up 3.0% year-over-year, and raised full-year adjusted EBITDA guidance to approximately $4.0 million, representing a 48.1% increase from 2025 adjusted EBITDA of $2.7 million.
International sales were $41.3 million, up 14.8%, while U.S. sales and rentals declined, and total gross margin improved to 45.5% from 44.8% a year earlier. GAAP net loss was $3.9 million compared with $4.2 million, and adjusted EBITDA increased to $2.4 million from $2.1 million. The company generated $2.9 million of operating cash flow in the quarter and ended June 30, 2026 with $106.8 million in cash, cash equivalents, marketable securities, and restricted cash and no debt, after repurchasing 1,145,150 shares for $7.5 million in the first half.
Operationally, Inogen reported publication of its QuOTE assessment tool for Long-Term Oxygen Therapy, launch of the Rove 6 portable oxygen concentrator in Canada, completion of Last Patient Last Visit for the Simeox H SCOPE Study in China, and the appointment of a new Chief Operating Officer.
Reding Andrew P. reported acquisition or exercise transactions in this Form 4 filing.
Inogen Inc executive Andrew P. Reding, EVP and COO, received a grant of 130,000 restricted stock units. Each unit represents the right to receive one share of Inogen common stock. One-third of the units will vest one year from September 1, 2026, with the remaining two thirds vesting in equal annual installments on the same date in subsequent years, subject to his continued service.
Inogen Inc executive Andrew P. Reding, who serves as EVP and COO, filed an initial Form 3 to report his status as an insider of the company. The filing lists no stock purchases, sales, option exercises, or other transactions, serving only as a baseline ownership report.
Inogen Inc executive Jennifer M. Yi Boyer, EVP Enterprise Enablement and Chief HR Officer, sold 10,938 shares of common stock in an open-market transaction on July 1, 2026 at a weighted average price of $6.5959 per share under a pre-arranged Rule 10b5-1 trading plan.
After this sale, she directly holds 5,039 shares of Inogen common stock.
INGN - Notice of proposed sale of Common stock. The filing lists a proposed sale under a 10b5-1 plan by Jennifer Yi Boyer reporting 10,770 shares dated 05/29/2026. The excerpt also records Restricted Stock Units dated 03/01/2025 with a quantity shown as 10,938 and identifies Morgan Stanley Smith Barney LLC as the broker.